ライフサイエンスコーパス: CMI

1 CMI analyses showed low levels of spot-forming cells aft

2 CMI assessment shortly after the onset of CMV viremia ma

3 CMI associates with TRR, as well as the EcR-USP receptor

4 CMI continues to be substantially more prevalent among d

5 CMI detection sensitivity and specificity of T1 CMR at 3

6 CMI prevalence was 28.9% among deployed veterans and 15.

7 CMI to a neoantigen was difficult to establish.

8 CMI to HAV was virtually absent.

9 CMI to M. avium reconstitutes rapidly after HAART and ap

10 CMI was measured in 31 patients at multiple time points

11 [CMI], Goleta, CA), an interactive telementoring system i

12 a stronger (P = .02) and broader (P = .013) CMI than patients with the CT genotype with chronically

13 Week 4 CMI was a strong predictor of PFS, even in the presence

14 deltao/o mice, which are unable to activate CMI against the parasite, suppress P. chabaudi infection

15 CL3L1-CCR5 genotypes associated with altered CMI in healthy subjects were similar to those that influ

16 ically derived from epibatidine, CMI-936 and CMI-1145, displayed reduced analgesic activity in both M

17 nsmurality relative to LGE images in AMI and CMI (P<0.001) at 1.5 T.

18 Resolution of edema between AMI and CMI was examined with T2 maps.

19 cell-mediated mechanism of immunity (AMI and CMI, respectively) or by both mechanisms.

20 Several antibody and CMI cytokine responses were examined for correlates of p

21 Antibody and CMI dose-exposure responses, albeit generally of low mag

22 Anti-PA antibody and CMI responses were detected in 94% and 86% of immunized

23 endently with both neutralizing antibody and CMI responses.

24 We previously designed an antibody- and CMI-inducing adjuvant based on poly(dl-lactic-co-glycoli

25 The overall SOC content and CMI in arable land were almost the lowest among three la

26 ation between IL28B.rs12979860 genotypes and CMI is suggestive of a possible important role of CMI in

27 ior TIV administration decreased humoral and CMI responses to A(H1N1)pdm09 vaccine.

28 Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, withou

29 years post-initial vaccination, humoral and CMI responses were ~6-fold and ~3.5-fold above pre-initi

30 pendently of their effects on viral load and CMI.

31 VLP serology and CMI responses may be the future intermediate surrogate b

32 SMI and CMI (compared with no MI) were associated with increased

33 However, SMI and CMI were associated with increased mortality among both

34 The incidence rates of both SMI and CMI were higher in men (5.08 and 7.96 per 1000-person ye

35 y posttransplant CMI risk stratification and CMI specific to the 65 kDa phosphoprotein (pp65) CMV ant

36 the expression phase of an anticryptococcal CMI response in mice.

37 were immunized to mount an anticryptococcal CMI response, our results indicate that immunization ind

38 nduction of a nonprotective anticryptococcal CMI response results in no significant increases in the

39 protective or nonprotective anticryptococcal CMI responses develop.

40 rotective and nonprotective anticryptococcal CMI responses.

41 n that induces a protective anticryptococcal CMI response and one that induces a nonprotective respon

42 Induction of a protective anticryptococcal CMI response includes increases in dendritic cells (DC)

43 earlier development of the anticryptococcal CMI response than in control mice.

44 design elicited the most robust and balanced CMI response.

45 ign capable of eliciting robust and balanced CMI responses to multiple HIV type 1 (HIV-1)-derived ant

46 V pathogenesis through their effects on both CMI and other viral entry-independent mechanisms.

47 e, CC genotype was associated with a broader CMI compared to CT genotype (P = .028).

48 transcription requires chromatin binding by CMI, methylation of H3K4 by TRR and demethylation of H3K

49 uppression of acute P. chabaudi infection by CMI is gammadelta T cell dependent, is independent of NK

50 the elimination of blood-stage parasites by CMI.

51 not accelerate or modulate the anti-Candida CMI response.

52 that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased apoptosis and s

53 nstrated a deeper depletion of preformed CMV CMI in R+ rATG-treated patients.

54 CMV-CMI was characterized as high when the intermediate-earl

55 CMV-CMI was low in patients who experienced CS-CMVi (94%), w

56 On multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid use

57 spective multicenter study, we evaluated CMV-CMI every 2 weeks from the pretransplant period until 6

58 CMVi (94%), whereas those who had a high CMV-CMI were less likely to have CS-CMVi (P < .0001).

59 CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immu

60 CMV cell-mediated immunity (CMV-CMI) can be determined by levels of interferon gamma (IF

61 ty (P = .007), especially those with low CMV-CMI (P = .035).

62 A strong association between low CMV-CMI and progression to CS-CMVi was observed in HCT recip

63 per 250 000 cells (cutoff 2), and a low CMV-CMI when SPCs were below these thresholds.

64 e implementation of serial monitoring of CMV-CMI may identify patients at risk of progression to CS-C

65 Measurement of CMV-CMI using a novel ELISPOT assay would be useful clinical

66 ithin 2 weeks of the last measurement of CMV-CMI.

67 methylation of host genes, and corresponding CMIs together with associated bacteria are potential bio

68 Seventy participants (28.8%) had cortical CMIs (median, 1; range, 0-43).

69 mulation of local Th1-type anti-cryptococcal CMI responses and the development of protective host imm

70 Fifteen-day CMI risk stratification better predicted CMV infection (

71 sed children who are receiving HAART develop CMI and antibody to a recall antigen independent of the

72 3.3%) developed SMI and 386 (4.1%) developed CMI.

73 he results indicate that a broad and durable CMI response to HIV DNA vaccines can be induced in a rel

74 gonists chemically derived from epibatidine, CMI-936 and CMI-1145, displayed reduced analgesic activi

75 sion, matched odds ratios (ORs) adjusted for CMI and confounders were estimated.

76 ple, distinct mechanisms are responsible for CMI.

77 immune mice, suggesting a critical role for CMI mechanisms in acquired protection in the CNS.

78 Historically, the treatment for CMI has been surgical revascularization.

79 etween-group difference at any follow-up for CMI (p > or = 0.33) or SSI (p > or = 0.08).

80 Further, CMI appeared as an independent risk factor for CRC diagn

81 e significantly shorter in women with a high CMI (PFS, 2.1 months; OS, 12.3 months) versus a low CMI

82 bacterial species in individuals with higher CMI in blood were identified by whole metagenomic analys

83 a subset of sporadic chronic mental illness (CMI), which modestly overexpresses human full-length, no

84 ntify cases of chronic multisymptom illness (CMI) based on the case definition from the Centers for D

85 (Gulf War I), chronic multisymptom illness (CMI) was more common among deployed veterans than among

86 infiltration during a cell-mediated immune (CMI) reaction.

87 are potent inducers of cell-mediated immune (CMI) response in mice but elicit poor HIV-specific IFN-g

88 ted persistence of the cell-mediated immune (CMI) response in rhesus macaques for at least 18 months

89 , we have examined the cell-mediated immune (CMI) response throughout the course of infection and com

90 a means of detecting a cell-mediated immune (CMI) response to the antigen.

91 The cell-mediated immune (CMI) response was characterized by significant gamma int

92 ctive vs nonprotective cell-mediated immune (CMI) responses against the fungal pathogen, Cryptococcus

93 )-specific humoral and cell-mediated immune (CMI) responses and the correlation between them, polyfun

94 Cell-mediated immune (CMI) responses and tumor necrosis factor alpha (TNF-alph

95 y virus (HIV)-specific cell-mediated immune (CMI) responses are critical in the early control and res

96 Cell-mediated immune (CMI) responses defined by delayed-type hypersensitivity

97 Postvaccination cell-mediated immune (CMI) responses have not been compared by use of controll

98 We evaluated cell-mediated immune (CMI) responses in mice given a pulmonary infection with

99 protective humoral and cell-mediated immune (CMI) responses in the genital tract mucosa.

100 istence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed throu

101 Cell-mediated immune (CMI) responses to hepatitis C virus (HCV) antigens in ad

102 Antibody and cell-mediated immune (CMI) responses to protective antigen (PA) and lethal fac

103 s, the role of AS03 on cell-mediated immune (CMI) responses, and vaccine safety.

104 sequences (wt-HAI) and cell-mediated immune (CMI) responses.

105 tion of virus-specific cell-mediated immune (CMI) responses.

106 ve a crucial role in cell-mediated immunity (CMI) against P. chabaudi malaria, but delta-chain knocko

107 The importance of cell-mediated immunity (CMI) and CD4(+) T lymphocytes in host resistance against

108 The CMV-specific cell-mediated immunity (CMI) at baseline and at different time points after tran

109 ody and VZV-specific cell-mediated immunity (CMI) at baseline, 8 weeks after each dose, and annually

110 Although cell-mediated immunity (CMI) by CD4 Th1-type cells is considered to be the predo

111 res the induction of cell-mediated immunity (CMI) for host survival.

112 Cell-mediated immunity (CMI) is critically important for protection against Eime

113 s suggest that local cell-mediated immunity (CMI) is more important than systemic CMI for protection

114 Although cell-mediated immunity (CMI) is the predominant host defense mechanism against m

115 Although Th1-type cell-mediated immunity (CMI) is the predominant host defense mechanism against m

116 Cs), suggesting that cell-mediated immunity (CMI) may play a role in viral clearance and protection f

117 ression of cutaneous cell-mediated immunity (CMI) reflected by nickel contact hypersensitivity (CHS).

118 specific humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ mor

119 l therapy (HAART) on cell-mediated immunity (CMI) to Mycobacterium avium complex (MAC), we measured i

120 ccine), which boosts cell-mediated immunity (CMI) to VZV and decreases the incidence and severity of

121 Cell-mediated immunity (CMI) to VZV was measured by an interferon-gamma (IFN-gam

122 nsplant CMV-specific cell-mediated immunity (CMI) using an interferon-gamma release assay to predict

123 Cell-mediated immunity (CMI) was measured shortly after viremia onset and longit

124 ntaneous recovery of cell-mediated immunity (CMI) was not seen for TT.

125 body concentrations, cell-mediated immunity (CMI), and immunoglobulin G (IgG) antibody avidity were a

126 protective role for cell-mediated immunity (CMI), humoral immunity, and innate resistance by neutrop

127 -1) relies mainly on cell-mediated immunity (CMI), the determinants of CMI in humans are poorly under

128 ted VZV-specific cellular mediated immunity (CMI).

129 979860 genotypes and cell-mediated immunity (CMI).

130 ated immunity and/or cell-mediated immunity (CMI).

131 n the development of cell-mediated immunity (CMI).

132 kers of VZV-specific cell-mediated immunity [CMI], measured by means of ELISPOT analysis) in individu

133 This increase in CMI responses translates to an apparent 50- to 200-fold

134 of the infarcted myocardium was increased in CMI and AMI (P<0.05), and T2 of the infarcted myocardium

135 um was increased in AMI (P<0.001) but not in CMI (P>0.20) at both field strengths.

136 07, respectively), which was not observed in CMI (P=0.49 and P=0.81, respectively) at 3 T.

137 A comorbidity index (CMI) was constructed.

138 d 60 months used the Craniomandibular Index (CMI) and Symptom Severity Index (SSI) for jaw function a

139 The carbon management index (CMI) was considered as the most effective indicator of s

140 = 1,000), the cumulative methylation index (CMI) of these genes was significantly higher in CRCs tha

141 A cumulative methylation index (CMI) was generated on the basis of six of the 10 genes t

142 FACS analysis, we characterized the induced CMI response.

143 aracterization of natural or vaccine-induced CMI to rotavirus.

144 sition within chronic myocardial infarction (CMI) influences the electric behavior of the heart.

145 against mucosal Candida albicans infection, CMI against a vaginal C. albicans infection in mice is l

146 ine CCL3L1 and HIV coreceptor CCR5 influence CMI in both healthy and HIV-infected individuals.

147 a patient with chronic mesenteric ischemia (CMI) for chronic loose, frequent, and urgent stools.

148 f patients with chronic mesenteric ischemia (CMI) who were treated with percutaneous stent revascular

149 S, 2.1 months; OS, 12.3 months) versus a low CMI (PFS, 5.8 months; OS, 21.7 months).

150 els, among women with MBC, a high versus low CMI at week 4 was independently associated with worse PF

151 Chiari Type I Malformation (CMI) is characterized by displacement of the cerebellar

152 cephalus (NPH), Chiari type I malformations (CMI), syringomyelia, and after neurosurgical procedures.

153 tudy showed that warthogs develop measurable CMI responses, which suggests that cytokine gene express

154 tant induction of both CD4- and CD8-mediated CMI are consistent with a significant role for type 1 im

155 l sham (C), Sildenafil sham (S), Control MI (CMI) and Sildenafil MI (SMI).

156 ence of MI without clinically documented MI (CMI) after the baseline until ARIC visit 4 (1996-1998).

157 s (acute MI [AMI]) and 4 months (chronic MI [CMI]) after MI.

158 Cortical cerebral microinfarcts (CMIs), a novel MRI marker of cerebral vascular disease,

159 ombination of ENZA and autophagy modulators, CMI or metformin significantly reduced tumor growth when

160 and macrophages, two cell types in a murine CMI reaction.

161 5 of 11 (45.5%) in patients with a negative CMI at onset (P=0.004).

162 A negative CMI was more frequently associated with CT genotype amon

163 fference was observed among R+ CMI-negative (CMI-) patients.

164 ufficient blood plasma samples and 97 had no CMI grading (none, incomplete, or ungradable MRI), leavi

165 Compared with participants with no CMIs, those with CMIs had a significantly higher prevale

166 ), Type 1B (mechano-insensitive nociceptors; CMI; n = 24), Type 2 (cold units; n = 2), Type 3 units (

167 zation during induction of the nonprotective CMI response had little effect on cellular and cytokine

168 two individuals presenting with nonsyndromic CMI with or without syringomyelia.

169 Interestingly, roughly 3-5% of CMI patients are diagnosed with KFS.

170 ify CCL3L1 and CCR5 as major determinants of CMI and demonstrate that these host factors influence HI

171 mediated immunity (CMI), the determinants of CMI in humans are poorly understood.

172 e healthy control group showed no effects of CMI.

173 immunospot (ELISPOT) assay for evaluation of CMI responses to rotavirus using frozen PBMCs obtained f

174 timulation is required for the expression of CMI against the parasite, we compared the time courses o

175 antigen-processing pathway for induction of CMI and antigen-specific cytotoxic T-lymphocyte response

176 This study demonstrates that the kinetics of CMI responses are different after primary vaccination ve

177 Here we have characterized the potency of CMI responses generated in mice and non-human primates a

178 nt study were to determine the prevalence of CMI among deployed and nondeployed veterans 10 years aft

179 ars; P=0.217), but whites had higher rate of CMI than blacks (5.04 versus 3.24 per 1000-person years;

180 like splenic LDC, are negative regulators of CMI responses.

181 most mucosal Candida infections, the role of CMI against vaginal candidiasis is uncertain, both in hu

182 s suggestive of a possible important role of CMI in favoring hepatitis C virus clearance in CC patien

183 ough much has been learned about the role of CMI in the clearance of C. neoformans from the lungs and

184 ine the location, size, and transmurality of CMI with high diagnostic accuracy.

185 taneous stent placement for the treatment of CMI can be performed with a high procedural success and

186 virus in natural infection and the vigor of CMI is modulated by the relative presence or absence of

187 disease may contribute to the development of CMIs.

188 ients developed VZV-specific antibody and/or CMI 2 months after 2 doses of vaccine, and 83% were resp

189 ZV induced strong humoral and polyfunctional CMI responses that persisted above pre-vaccination level

190 At baseline, a positive CMI test (interferon-gamma>/=0.2 IU/mL) was present in 2

191 In patients with a positive CMI, the incidence of subsequent spontaneous viral clear

192 In R+ CMI-positive (CMI+) patients, the CMV DNAemia rate was higher in rATG-

193 Also, 15-day posttransplant CMI risk stratification and CMI specific to the 65 kDa p

194 Similarly, potent CMI responses were induced by the gag/pol regimen, as me

195 at high risk for CMV based on pretransplant CMI developed significantly higher CMV infection rates t

196 s a potentially modifiable factor to prevent CMI-related brain injury.

197 functions during induction of the protective CMI response by influencing the accumulation of all thre

198 atients; no difference was observed among R+ CMI-negative (CMI-) patients.

199 In R+ CMI-positive (CMI+) patients, the CMV DNAemia rate was h

200 described 3 groups, the least prone being R+CMI+ KTRs without rATG, then R+CMI+ KTRs with rATG, and

201 G, then R+CMI+ KTRs with rATG, and finally R+CMI- KTRs.

202 prone being R+CMI+ KTRs without rATG, then R+CMI+ KTRs with rATG, and finally R+CMI- KTRs.

203 (682 vaccinees and 680 placebo recipients), CMI was measured by VZV responder cell frequency and int

204 War cohort, a higher prevalence of reported CMI was noted among deployed compared with nondeployed c

205 The prevalence of self-reported CMI symptoms was compared with that collected in 1997-19

206 ng the use of cell-mediated immune response (CMI) assays.

207 mphoproliferative cellular immune responses (CMI) to HPV 16 peptides are not associated with CD4 coun

208 at eliciting cell-mediated immune responses (CMI).

209 Similarly, CMI and avidity analyses showed minimal qualitative impr

210 ith connective tissue disorders (CTDs) since CMI and CTDs frequently co-occur and it has been propose

211 In combination with SOC, CMI and soil physical properties, we argued that alfalfa

212 In some CMIs but in none of the CMRs, the supernormal period was

213 ine CMV (immediate-early protein 1)-specific CMI risk, were randomized to receive either preemptive o

214 capable of eliciting HIV-1 antigen-specific CMI responses in mice.

215 Pretransplant CMV-specific CMI identifies D+/R+ kidney recipients at high risk of d

216 Monitoring CMV-specific CMI may guide decision making regarding the type of CMV

217 Monitoring CMV-specific CMI soon after transplantation further defines the CMV i

218 The predictive capacity for CMV-specific CMI was only found in basiliximab-treated patients for b

219 CMV serostatus, baseline CMV-specific CMI, and induction therapy may lead to personalized prev

220 ells (PBMCs) were evaluated for HCV-specific CMI responses by interferon gamma (IFN-gamma) enzyme-lin

221 We investigated HCV-specific CMI responses in seronegative children living with HCV-i

222 inia-nonnaive individuals, vaccinia-specific CMI responses were detected by day 7 after vaccination a

223 assess the time course of vaccinia-specific CMI responses, 20 previously vaccinated and 10 vaccinia-

224 that a residual effect of ZV on VZV-specific CMI persisted for >/= 10 years and was enhanced by the b

225 In most subjects, VZV-specific CMI was increased at 6 weeks postvaccination.

226 th baseline and postvaccination VZV-specific CMI were lower in the older age groups.

227 er baseline and postvaccination VZV-specific CMI.

228 June temperature (r = 0.40) and prior summer CMI (r = 0.40) from 1938 to 2007.

229 robotic arm and Hermes voice command system (CMI).

230 e a lack of demonstrable effects by systemic CMI or PMN against vaginitis and suggest that if local T

231 at deficiencies in Candida-specific systemic CMI account solely for the susceptibility to OPC.

232 study investigated Candida-specific systemic CMI in HIV-positive persons with OPC and/or VVC.

233 munity (CMI) is more important than systemic CMI for protection against vaginitis.

234 B10.D2 CD4 T cells induce a strong Th1/CMI pathway that is characterized by IL-2/IFN-gamma expr

235 These data demonstrate that CMI is sufficient for vaccine protection from intestinal

236 In order to investigate the possibility that CMI and KFS are allelic, GDF3 and GDF6 were sequenced le

237 ently co-occur and it has been proposed that CMI patients with CTDs represent a distinct class of pat

238 Unexpectedly, although the CMI and MLL2 PHDf3 domains could bind histone H3, neithe

239 s were used to test associations between the CMI and progression-free survival (PFS), overall surviva

240 An increase in the CMI from baseline to week 4 was associated with worse PF

241 The added value of the CMI in predicting survival outcomes was evaluated and co

242 ot available for the expression phase of the CMI response.

243 ed extensive replacement fibrosis within the CMI territories.

244 The CMIs showed a greater tendency towards supernormality, w

245 The CMIs were graded according to a previously validated pro

246 significantly upregulated in SMI compared to CMI.

247 igand binding studies indicated that the two CMI compounds, in contrast to oxotremorine, showed >6-fo

248 In contrast, Th1-type CMI is highly effective against an experimental Chlamydi

249 vant system EM014 elicited a potent Th1-type CMI profile and provided significant protection, as meas

250 VZV CMI responses to HZ were similar in zoster vaccine and p

251 and zoster vaccine generated comparable VZV CMI.

252 zoster vaccine and HZ could be compared, VZV CMI values were similar, but antibody titers were lower.

253 Higher VZV CMI at HZ onset was associated with reduced HZ severity

254 Robust VZV CMI at HZ onset correlated with reduced HZ morbidity, wh

255 VZV-CMI and VZV antibodies were significantly increased in v

256 VZV-CMI correlated with lower HIV load but not with CD4 cell

257 VZV-CMI declines greatly with aging, but can be restored by

258 VZV-CMI did not change over the course of >/=3 years of obse

259 VZV vaccines can boost VZV-CMI.

260 ngs support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and post

261 the 2 HAART-compliant patients developed VZV-CMI.

262 Depressed patients have diminished VZV-CMI responses to zoster vaccine, and treatment with anti

263 ts who developed HZ during the study had VZV-CMI before developing HZ.

264 for VZV-specific cell-mediated immunity (VZV-CMI) by gamma-interferon ELISPOT and responder cell freq

265 s (VZV)-specific cell-mediated immunity (VZV-CMI) in 56 VZV- and HIV-infected children.

266 er virus (VZV) T-cell-mediated immunity (VZV-CMI) in older persons prevents latent VZV in sensory neu

267 lla-zoster virus cell-mediated immunity (VZV-CMI) of adults >=70 years who received a second dose of

268 s (VZV)-specific cell-mediated immunity (VZV-CMI).

269 However, the vaccine-induced boost in VZV-CMI (which determines the efficacy of the vaccine) is a

270 accine induced a significant increase in VZV-CMI and VZV antibody.

271 In conclusion, the increase in VZV-CMI generated by reimmunization with ZVL is at least equ

272 phenotypic and functional differences in VZV-CMI in old and young persons are reviewed, as well as th

273 e magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this b

274 The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although

275 Because higher levels of VZV-CMI correlate with lower risk and severity of HZ, untrea

276 pressant medications had lower levels of VZV-CMI following administration of zoster vaccine than nond

277 a peak threefold to fourfold increase of VZV-CMI; the VZV weekly reactivation probability at 5% and V

278 odel that integrates within-host data on VZV-CMI and between-host transmission data to simulate HZ in

279 linical reactivation having no effect on VZV-CMI.

280 ession or other mental illness had their VZV-CMI measured prior to vaccination with zoster vaccine or

281 during the first year after vaccination, VZV-CMI was significantly higher in reimmunized compared wit

282 At 3 years, VZV-CMI differences between groups decreased and only memory

283 These findings indicate that a weak CMI response contributes to prolonged PRRSV infection an

284 isorder) and depression were associated with CMI among both deployed and nondeployed veterans.

285 nfectious mononucleosis were associated with CMI among deployed veterans, and migraine headaches and

286 headaches and gastritis were associated with CMI among nondeployed veterans.

287 and identify prewar factors associated with CMI.

288 gnant ventricular arrhythmias in humans with CMI is unknown.

289 Patients with CMI (n=94) who underwent late-gadolinium-enhanced cardia

290 se, frequent stools with FI in patients with CMI in this difficult to manage gastrointestinal populat

291 Patients with CMI show abnormalities in CSF dynamics within the subara

292 Fifty-nine consecutive patients with CMI underwent stent placement in 79 stenotic (>70%) mese

293 Deployed and nondeployed veterans with CMI had similarly poorer quality-of-life measures and hi

294 nifest cardiac diseases were associated with CMIs on 3-T MRI in patients attending a memory clinic, s

295 .86; 95% CI, 3.03-7.08) were associated with CMIs.

296 nd clinically manifest cardiac diseases with CMIs graded on 3-T MRI in a memory clinic population.

297 , 1.00-4.74) were found in participants with CMIs.

298 d with participants with no CMIs, those with CMIs had a significantly higher prevalence of atrial fib

299 Hypointense cores within CMI on balanced steady-state free precession cardiac mag

300 The use of HIC within CMI on balanced steady-state free precession as a marker

301 d steady-state free precession images within CMI likely result from iron depositions.